

92
COSTIGAN

triclosan and a cationic antimicrobial compound which is effective to alleviate the symptoms of said fungal infection.

Kindly cancel claims 2-6, 8-17 and 26

REMARKS

The personal interview with the Examiner, Barry Libin and the undersigned on August 19, 1999 is acknowledged. It was agreed that a terminal disclaimer would be filed in this case.


The Terminal Disclaimer is attached to this Amendment along with a Certificate Under 37 CFR§3.73.

Copies of the Information Disclosure Statements from related application Serial No. 08/798,504 are enclosed to complete the record of the present application. Copies of the materials cited in the Information Disclosure Statements are of record in Serial No. 08/798,504 and additional copies will be provided upon request.

The claims have been amended to point out the preferred embodiments. The claims have been amended to delete the reference to mucositis apart from a composition that includes a fluoride. Claim 1 has also been limited to the use of a combination of triclosan and a cationic antimicrobial compound. Claim 23 has been amended to point out a method of treating a fungal infection using a combination of triclosan and an antibacterial agent.


Authorization is given to charge any fee that is required in connection with the Terminal Disclaimer to Deposit Account No. 08-1540.

Respectfully submitted,


James V. Costigan
Reg. No. 25,669

Hedman, Gibson & Costigan, P.C.
1185 Avenue of the Americas
New York, NY 10036

I hereby certify that this correspondence is being deposited with the United States Postal Service in first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231, on 12-26-99


Reg No 25,669